Abstract: Among the various aspects of the present disclosure is the provision of a method of treating a neurodegenerative disease in a subject in need thereof comprising administering a therapeutically effective amount of a TAR DNA-binding protein (TDP-43) modulating agent comprising an RNA oligonucleotide.

Abstract: The present disclosure provides compositions and method targeting GPER for the treatment of cancers, such as breast cancers and leukemias, gallstone disease, and for conferring of neuroprotection on a subject. Also disclosed are high throughput assays for identifying antagonists of GPER.

Abstract: The present invention generally relates to various polycyclic aromatic selenoxide compounds, methods for preparing these compounds, and methods of us these and other compounds to generate ground state atomic oxygen.

Abstract: A two-factor authentication system includes a mobile device having a vibration element configured to generate a vibration sequence based on a unique vibration code received by the mobile device. A two-factor authentication server is communicatively coupled to the mobile device and is configured to send the unique vibration code to the mobile device in response to the two-factor authentication server receiving a two-factor authentication request. A vibration receiver is configured to support the mobile device and communicatively coupled to the two-factor authentication server. The vibration receiver includes a vibration sensor configured to detect the vibration sequence generated by the mobile device based on the unique vibration code and generate a vibration authentication signal based on the detected vibration sequence.

Abstract: Disclosed are methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). Also disclosed are methods of inducing oral tolerance towards a target enzyme through oral administration of immunodominant peptides prior to commencing enzyme replacement therapy. More specifically disclosed is a method of inducing oral tolerance for GALNS, by orally administering specific immunodominant peptides for GALNS; in subjects suffering from mucopolysaccharidosis type IVA prior to commencing enzyme replacement therapy using GALNS.

Abstract: A telepathology system is associated with an edge network shared among participating users for remote control of a microscope. The microscope includes a camera operable to receive image data of a specimen. The telepathology system is capable of receiving image data from the microscope, pre-processing the image data at network edge, sending the pre-processed image digitally to the participating users via a web server on the edge network, and controlling the image data, via instructions from the participating users.

Abstract: The present disclosure provides inhibitors of microorganisms including viruses and fungi of the formula (I) or (II) wherein the variables are defined herein. Also provided are methods of treatment using these agents in the treatment of infections of microorganisms such as viruses and fungi.

Abstract: Provided herein are compounds of the formula: wherein the variables are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds may be used for the treatment of diseases or disorders, such as an infection of an antibiotic resistant bacteria.

Abstract: The present disclosure relates to inhibitors of herpesvirus nucleic acid metabolism and inhibitors of Hepatitis B virus. Also provided are methods of treatment using these agents.

Abstract: Disclosed are fluidic devices and methods for preparing fluidic devices. More particularly, disclosed are fluidic devices having fiber scaffolds and methods for their preparation. Also disclosed are methods for culturing cells using the fluidic devices having fiber scaffolds.

Abstract: The present invention relates to methods and systems that provide for a human liver perfusion model with dual blood supply channels, permitting two liver lobes split from the same donor to be pumped simultaneously for rigorously controlled therapeutic testing.

Abstract: The present disclosure provides compositions and methods for inhibiting T cell senescence and improving T cell immunotherapies. In particular, inhibitors of group IV A phospholipase A2 are disclosed as useful in modulating the lipid metabolism of cells, in particular effector T cells, such that T reg- and tumor cell-induced cell senescence is abrogated. These methods may be employed with particular utility in adoptive T cell therapies and/or enhanced T cell effector functions in vivo, including those performed in combination with checkpoint blockade therapies.

Abstract: The present disclosure generally relates to face masks that provide for enhanced acoustics for speech and singing. The face masks are preferably made of acoustically transparent material to minimize the effect the face masks have on the sound produced by a person speaking and/or singing.

Abstract: The present disclosure generally relates to systems and methods for guiding surgical tools to a surgical site, and more particularly, to systems and methods for guiding a tool sheath of a delivery system to a surgical site such as a location in a subject's brain and associated surgical procedures.

Abstract: The disclosure provides for new epidermal growth factor (EGF)-based reagents that have been modified by fatty acid conjugation. Method of using such agents to treatment Short Bowel Syndrome (SBS) are also described.

Abstract: The present disclosure provides pharmaceutical agents, including those of the formula: (I) wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents are also provided. The compounds may be used for the inhibition or antagonism of integrins ???? and/or ?5??. In some embodiments, the compounds provided herein exhibit reduced inhibitory or antagonistic activity of integrins ???3, ???5, ???6, ???8, and/or ?IIb?3.

Abstract: In some aspects, the present disclosure provides germ cell nuclear factor ligands of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions and methods of use thereof. Also provided are cell cultures and cell culture media comprising the GNCF ligands of the present disclosure as well as methods of use thereof.

Abstract: The present disclosure provides BET inhibitors of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods of treating a patient comprising administering a bromo- and extra-terminal (BET) domain inhibitor for the treatment of FSHD which modulates DUX4 expression. In some embodiments, the present methods comprise using one or more BET inhibitors as a therapeutic agent for the treatment of FSHD patients including patients who are being treated with one or more palliative treatments such as therapy and/or agents which lead to increased muscle mass.

Abstract: Disclosed herein are compounds and methods for labeling and quantifying analytes using mass spectrometry.

Abstract: The present disclosure provides inhibitors of bunyavirus of the formula: wherein the variables are defined herein.